Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide – A randomised controlled trial. (February 2015)
- Record Type:
- Journal Article
- Title:
- Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide – A randomised controlled trial. (February 2015)
- Main Title:
- Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide – A randomised controlled trial
- Authors:
- George, Anne
Mathews, Jiji E.
Sam, Dibu
Beck, Manisha
Benjamin, Santosh J.
Abraham, Anuja
Antonisamy, Balevendra
Jana, Atanu K.
Thomas, Nihal - Abstract:
- <abstract abstract-type="main" id="ajo12265-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="ajo12276-sec-0001" sec-type="section"> <title>Background</title> <p>Two oral hypoglycaemic agents, metformin and glibenclamide, have been compared with insulin in separate large randomised controlled trials and have been found to be as effective as insulin in gestational diabetes. However, very few trials have compared metformin with glibenclamide.</p> </sec> <sec id="ajo12276-sec-0002" sec-type="section"> <title>Materials and Methods</title> <p>Of 159 South Indian women with fasting glucose ≥5.5 mmol/l and ≤7.2 mmol/l and/or 2‐h post‐prandial value ≥6.7 mmol/l and ≤13.9 mmol/l after medical nutritional therapy consented to be randomised to receive either glibenclamide or metformin. 80 women received glibenclamide and 79 received metformin. Neonatal outcomes were assessed by neonatologists who were unaware that the mother was part of a study and were recorded by assessors blinded to the medication the mother was given. The primary outcome was a composite of neonatal outcomes namely macrosomia, hypoglycaemia, need for phototherapy, respiratory distress, stillbirth or neonatal death and birth trauma. Secondary outcomes were birthweight, maternal glycaemic control, pregnancy induced hypertension, preterm birth, need for induction of labour, mode of delivery and complications of delivery.</p> </sec> <sec id="ajo12276-sec-0003" sec-type="section"><abstract abstract-type="main" id="ajo12265-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="ajo12276-sec-0001" sec-type="section"> <title>Background</title> <p>Two oral hypoglycaemic agents, metformin and glibenclamide, have been compared with insulin in separate large randomised controlled trials and have been found to be as effective as insulin in gestational diabetes. However, very few trials have compared metformin with glibenclamide.</p> </sec> <sec id="ajo12276-sec-0002" sec-type="section"> <title>Materials and Methods</title> <p>Of 159 South Indian women with fasting glucose ≥5.5 mmol/l and ≤7.2 mmol/l and/or 2‐h post‐prandial value ≥6.7 mmol/l and ≤13.9 mmol/l after medical nutritional therapy consented to be randomised to receive either glibenclamide or metformin. 80 women received glibenclamide and 79 received metformin. Neonatal outcomes were assessed by neonatologists who were unaware that the mother was part of a study and were recorded by assessors blinded to the medication the mother was given. The primary outcome was a composite of neonatal outcomes namely macrosomia, hypoglycaemia, need for phototherapy, respiratory distress, stillbirth or neonatal death and birth trauma. Secondary outcomes were birthweight, maternal glycaemic control, pregnancy induced hypertension, preterm birth, need for induction of labour, mode of delivery and complications of delivery.</p> </sec> <sec id="ajo12276-sec-0003" sec-type="section"> <title>Results</title> <p>Baseline characteristics were similar but for the higher fasting triglyceride levels in women on metformin. The primary outcome was seen in 35% of the glibenclamide group and 18.9% of the metformin group [95% CI 16.1 (2.5, 29.7); <italic>P</italic> = 0.02]. The difference in outcome related to a higher rate of neonatal hypoglycaemia in the glibenclamide group (12.5%) versus none in the metformin group [95% CI 12.5(5.3, 19.7); <italic>P</italic> = 0.001]. Secondary outcomes in both groups were similar.</p> </sec> <sec id="ajo12276-sec-0004" sec-type="section"> <title>Conclusion</title> <p>In a south Indian population with gestational diabetes, metformin was associated with better neonatal outcomes than glibenclamide.</p> </sec> </abstract> … (more)
- Is Part Of:
- Australian and New Zealand journal of obstetrics and gynaecology. Volume 55:Number 1(2015:Feb.)
- Journal:
- Australian and New Zealand journal of obstetrics and gynaecology
- Issue:
- Volume 55:Number 1(2015:Feb.)
- Issue Display:
- Volume 55, Issue 1 (2015)
- Year:
- 2015
- Volume:
- 55
- Issue:
- 1
- Issue Sort Value:
- 2015-0055-0001-0000
- Page Start:
- 47
- Page End:
- 52
- Publication Date:
- 2015-02
- Subjects:
- Obstetrics -- Periodicals
Gynecology -- Periodicals
618.05 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1479-828X ↗
http://www.blackwell-synergy.com/loi/ajo ↗
http://www3.interscience.wiley.com/journal/118501330/home ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/ajo.12276 ↗
- Languages:
- English
- ISSNs:
- 0004-8666
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 1796.890000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 3931.xml